[A Case of Long-Term Survival after Administration of Regorafenib for Stage â £ Colorectal Cancer].

The patient was a 65-year-old man for whom a right hemicolectomy was performed for transverse colon cancer and multiple lymph node metastases. Peritoneal dissemination was observed throughout the abdominal cavity, and curative resection was not possible. Postoperative diagnosis: pT4bN2M1c(P3), Stage Ⅳc, and mutant RAS status. Therapy consisting of mFOLFOX6 plus bevacizumab was started 1 month after surgery, and up to 25 courses were completed. FOLFIRI plus bevacizumab therapy was performed up to 13 courses as the second-line therapy. Regorafenib 80 mg/day was started as the third-line therapy and the dose was gradually increased. It was performed up to 14 courses for about 13 months, without major adverse events, to keep the disease stable or slow its progression. Although up to 5 courses of FTD/TPI plus bevacizumab therapy were delivered as the fourth-line therapy, he died of disease progression. Regorafenib, which has been approved as a salvage line for metastatic colorectal cancer, features many adverse events, and there are few cases in which the approved dose can be administered. In our case, starting at a low dose resulted in fewer adverse events, adequate disease control, and long-term administration.

[A Case of Neuroendocrine Carcinoma of the Ascending Colon That Responded Completely to Chemotherapy].

We report a case of effective treatment comprising mFOLFOX6 plus bevacizumab for neuroendocrine carcinoma of the ascending colon. A 60-year-old woman was admitted for diarrhea and abdominal pain. Colonoscopy showed a Type 2 tumor in the ascending colon. She was diagnosed with neuroendocrine cell carcinoma based on biopsy and immunostaining. CT and MRI showed liver metastasis and lymph node #12a metastasis. Right hemi-colectomy, lymphadenectomy, and partial hepatectomy were performed(T4a, N2, M1b, Stage IV). Neuroendocrine cell carcinoma(small-cell type)was finally diagnosed based on a histological examination because the nuclear fission image was 30(/10HPF)and the Ki-67 index was 42%. Three months after the surgery, multiple lymph node metastases were found using CT and MRI. mFOLFOX6 plus bevacizumab was initiated. After 4 courses of the chemotherapy, the metastases responded completely. A total of 10 courses of chemotherapy were administered. About 2 years and 6 months after the surgery, no recurrence is allowed.

[Application of Ultrasonography in Detecting Multiple Schwannomas from a Single Intercostal Nerve;Report of a Case].

A 31-year-old man was referred to our hospital for chest abnormal shadow on a routine health checkup. Two nodular lesions were found at the 2nd intercostal space by computed tomography. Chest wall ultrasonography showed 2 masses suspecting tumors. Tumors were resected through 3-cm skin incision with the assistance of thoracoscope. Pathological diagnosis was both schwannomas. Ultrasonography was useful in resecting chest wall tumor.

Successful rechallenge with cetuximab after an infusion related reaction to panitumumab in a patient with locally advanced rectal cancer.

Incidence of infusion related reaction (IR) is more common with cetuximab (Cmab) than with panitumumab (Pmab). Although little is known about rechallenge IR with monoclonal antibodies, we experienced a successful rechallenge to Cmab after IR to Pmab. A 67-year-old female patient was scheduled for chemotherapy with mFOLFOX6 plus Pmab against unresectable advanced rectal cancer in the hope of tumor shrinkage. On the first administration of Pmab, she complained of dyspnea with shortness of breath and wheezing, even after premedication with steroids and antihistamines. Her reaction was judged as Grade 2 IR to Pmab. For the next course, we tried Cmab. No IRs were observed. Since then, she has undergone seven further courses of treatment, followed by surgical resection. The patient benefited from administration of Cmab after experiencing IR to Pmab, suggesting this treatment to be an option for patients of this type who experience IR to Pmab.

Bronchial artery embolization: first-line option for managing massive hemoptysis.

Background Today, treatment for hemoptysis is not limited to surgery, and among the various options, bronchial artery embolization is regarded as an effective approach. Methods In this retrospective study, 179 of 389 patients with massive hemoptysis were treated with bronchial artery embolization, without taking into account the underlying pathological lesions responsible (bronchiectasis in 41, aspergilloma in 29, lung cancer in 25, old tuberculosis in 23, pyothorax in 19, others in 23). Results Bronchial artery embolization failed in 12 cases. In the 167 successful cases, surgery was required in 16 and bronchial occlusion was performed in 4; 3 patients died due to recurrent massive hemoptysis. After bronchial artery embolization, thoracic surgery for reasons other than hemostasis was carried out in 15 patients. Bronchial artery embolization was performed in 31 patients with hemoptysis who had a history of chest surgery. Four patients underwent bronchial occlusion, and immediate hemostasis was achieved in all of them. Conclusions For treatment of hemoptysis, bronchial artery embolization is a safe and minimally invasive technique that can be performed repeatedly, and provides not only short-term but also prolonged effectiveness; thus it can be used as a first-line treatment irrespective of the underlying pathological lesion. Bronchial occlusion may be useful for emergency hemostasis, but it warrants careful follow-up with consideration of additional elective treatment such as bronchial artery embolization.

Fabricated bronchial artery embolization for hemoptysis using a coil.

BACKGROUND: Bronchial artery embolization is considered a conservative form of therapy for hemoptysis. This study aimed to examine the short- and long-term effects of bronchial artery embolization, as well as the performance of the coils used in our hospital. METHODS: We reviewed the background, symptoms, findings, and prognosis of 27 cases of bronchial artery embolization for hemoptysis between April 2003 and October 2011. For embolization materials, short coils combined with a long interlocking detachable coil were mainly used from March 2008. RESULTS: Aspergillosis and chronic empyema comprised the majority of cases. In terms of short-term results, there were 25 successful cases of bronchial artery embolization and 2 unsuccessful cases. Regarding the long-term outcome of the successful cases, during an average observation period of 17 months, one patient required repeat bronchial artery embolization, and one was admitted to another hospital with recurrent hemoptysis. CONCLUSIONS: Bronchial artery embolization for hemoptysis was preformed in a safe and minimally invasive manner with positive results over both the short- and long-term, thus underscoring its utility as a form of treatment. Furthermore, by combining the use of long and short coils, we were able to reduce the number of coils necessary for the procedure, and thus reduce the time and cost involved.

Transient occlusion procedure with a catheter for peripheral pulmonary artery damage caused by percutaneous drainage for lung abscess.

The patient was a 78-year-old man who had liver and lung abscesses. Percutaneous drainage was performed for the lung abscess. While the drainage was successful for both abscesses, a drainage tube injured the peripheral pulmonary artery, causing hemorrhage and hemosputum. An occlusion technique for the pulmonary basal artery using a wedged barman catheter stopped the bleeding, resulting in a successful outcome.